GLP-1 receptor
GLP 1 receptor agonists show neuroprotective effects in animal models of diabetes
... 2017). GLP-1 receptors are expressed in the brains of rodents, primates and humans (Merchenthaler et ...2016). GLP-1 receptor agonists such as exendin- 4 or liraglutide can reverse ...
20
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
... all GLP-1 receptor agonists affect both the basal and prandial com- ponents of hyperglycemia in patients with type 2 diabe- tes, although the main mechanism by which they reduce postprandial ...
9
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
... of GLP-1 receptor agonist [5, 17] and metformin or com- bination of roflumilast and metformin [10], which might suggest a possible additive role of metformin to GLP-1 mediated effect ...
8
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
... Methods: The records of 43 patients with type 2 diabetes who started receiving GLP-1 receptor agonist therapy during hospitalization were retrospectively reviewed. Glucagon stimulation tests were ...
8
Emerging role of GLP-1 receptor agonists in the treatment of obesity
... hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for the ...
11
Role and development of GLP-1 receptor agonists in the management of diabetes
... exogenous GLP-1 – increasing insulin secretion from β cells, suppressing gluca- gon secretion from α cells, decreasing post-prandial glucose excursion through delay in gastric emptying, increasing post- ...
13
Efficacy and Safety of Basal Supported Prandial GLP 1 Receptor Agonist Therapy
... Overall, while no difference was observed in HbA1c over the 4-month study pe- riod, a 1.5 kg decrease in body weight was observed (p < 0.001). There was no change in the frequency of hypoglycemia. Hypoglycemia and ...
10
A mechanism for agonist activation of the glucagon-like peptide-1 (GLP-1) receptor through modelling & molecular dynamics
... in 1]. As such, the GLP-1 receptor (GLP-1R) has been successfully targeted for anti-diabetic and anti-obesity therapy through the discovery of a number of peptidic GLP-1 ...
37
A comparison of three 67/68Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator
... The GLP-1 receptor is specifically expressed on β-cells and is a promising target for β-cell ...for GLP-1R, have been successfully used to image insulinoma in patients ...the ...
10
GLP-1 RECEPTOR ACTIVATION-BASED THERAPY; A PROMISING STRATEGY AGAINST ISCHEMIC STROKE
... (GLP-1) receptor agonists are novel antidiabetic agents with a proved neuroprotection ...of GLP-1 use as a neuroprotective approach against DM-associated ...
6
Pancreatic GLP 1 receptor activation is sufficient for incretin control of glucose metabolism in mice
... cells. GLP-1 also modulates gastric emptying and engages neural circuits in the portal region and CNS that contribute to GLP-1 receptor–dependent (GLP-1R–dependent) regulation of ...
16
Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1
... of GLP-1 is not only to decrease blood sugar, but also acts as a neurotrophic factor that plays a role in neuronal survival, neurite outgrowth, and protects synaptic plasticity and memory formation from ...
13
Extra Glycemic Impacts of GLP 1 Receptor Agonists: Benefits of a Class Effect?
... the GLP-1 receptor and less fluctu- ations in peptide levels ...at 1 mmol/L more than exena- tide [34] [40] ...the GLP-1 RAs has been compared to exenatide or liraglutide, the ...
15
GLP 1 receptor agonists for Parkinson's disease (Protocol)
... of GLP-1 receptor agonists for PD, as this will provide a summary of the current state of the evidence, as well as providing a platform for updating the evidence base as future studies ...
14
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
... [GLP-1] receptor agonists and dipeptidyl peptidase-4 [DPP-4] inhibitors) have become fundamental treatment options, with GLP-1 receptor agonists having higher status in both sets ...
10
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
... two GLP-1 receptor agonist medications, the most important factors in patients’ decisions in rank order were: “dosing frequency,” “type of delivery device,” “frequency of nausea,” “weight change,” ...
12
Promotion of apoptosis in high glucose-activated hepatic stellate cells by GLP-1 receptor agonist and its potential mechanism.
... that GLP-1RA has an anti-fibrosis effect on several organs, including the ...that GLP-1 receptor can be detected on the surface of HSCs Wu LK, (2013), et ...of GLP-1RA might also be ...
7
The GLP 1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK dependent mechanism
... Results: Time course experiments show that EXE increases glucose uptake up to 48 h achieving its maximal effect, similar to that induced by insulin, after 20 min (2- vs 2.5-fold-increase, respectively). Differently from ...
13
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
... Different GLP-1R directed polyclonal antibodies have produced variable results regarding the existence or extent of GLP1R in exocrine pancreas or pancreatic ductal cells [43, ...
25
The arcuate nucleus mediates GLP 1 receptor agonist liraglutide dependent weight loss
... rats (12–13 weeks of age) underwent APx or a sham surgery (sham). Rats were anesthetized with a mixture of ketamine (63 mg/kg) and xylazine (9.4 mg/kg) mixed 4:3 (0.1 ml/100 g body weight) and were maintained at 36°C to ...
17